Earnings Per Common Share Attributable to Common Shareholders (Tables)

3 Months Ended

Mar. 29, 2020

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Earning Per Share

The following table provides the detailed calculation of EPS:
	Three Months Ended
(IN MILLIONS)	March 29, 2020		March 31, 2019
EPS Numerator––Basic
Income from continuing operations	$	3,410	$	3,889
Less: Net income attributable to noncontrolling interests	9		6
Income from continuing operations attributable to Pfizer Inc.	3,401		3,884
Less: Preferred stock dividends––net of tax	—		—
Income from continuing operations attributable to Pfizer Inc. common shareholders	3,401		3,883
Discontinued operations––net of tax	—		—
Net income attributable to Pfizer Inc. common shareholders	$	3,401	$	3,883
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	3,401	$	3,884
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	—		—
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	3,401	$	3,884
EPS Denominator
Weighted-average number of common shares outstanding––Basic	5,545		5,635
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock	68		115
Weighted-average number of common shares outstanding––Diluted	5,613		5,750
Anti-dilutive common stock equivalents(a)	3		2

^(a) 

These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.